Pharmaceutical Executive-05-01-2013

New research from the Tufts Center for the Study of Drug Development identifies a significant contributor to the rising cost of clinical trials-the first step in meeting a growing strategic imperative to help senior management and the regulatory community craft new approaches to make trials more efficient in delivering results to clinicians and patients.

Value-based pricing in the United Kingdom is getting closer, but it remains out of focus.

While Austria experienced significant political and economic shake-up throughout the 20th century, the country has remained a key strategic market for the pharmaceutical industry thanks to its steady economic development and inclination for innovation.

S

What is industry icon Fred Hassan's management formula for staying fresh in an era of market churn?

A night of comedy in support of a chronic disease.

Patent expiries dampen revenues for some of the biggest Big Pharma, but growth continues unabated for a few nimble "stealth" players moving steadily up the list.

New approaches to managing reimbursements for pharmacy benefit programs are testing Big Pharma.

Last month's decision by India's Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve-but the implications in and beyond India are both immediate and lasting.

In the world of patient education, processes, policies, and oversight differ vastly. There is no overarching governance structure. There isn't an accreditation process for educational interventions or patient advocacy organizations that develop the education.

For the hard-pressed oncology practice, new technologies hold the key to surviving-and thriving.

Legal battles and regulatory missteps undermine access to low-cost generics, at home and abroad, writes Jill Wechsler.